United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

The US Food and Drug Administration (FDA) has said it intends to authorize Pfizer and BioNTech's COVID-19 vaccine. It "will rapidly work toward finalization and issuance of an emergency use authorization" for Pfizer's shot, it said Friday morning. The vaccine would be the first to be authorized for use in the US.

The FDA says it will authorize Pfizer's COVID-19 vaccine, which could be rolled out as early as Monday

ROCKLAND, Mass. and NEW YORK, Dec. 11, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...

BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

A key FDA advisory panel overwhelmingly endorsed the Pfizer's Covid-19 vaccine Thursday evening.

FDA chief says agency will quickly approve Pfizer's Covid vaccine for emergency use.

The Food and Drug Administration plans to finalize and issue an emergency use authorization to BioNTech and Pfizer Inc.'s experimental COVID-19 vaccine, the regulator said Friday. Shares of BioNTech gained 1.5% in premarket trading on Friday, while Pfizer's stock was up 2.1%.

FDA said it plans to issue emergency authorization to BioNTech/Pfizer's COVID-19 vaccine

Pfizer Inc. said Friday's its board has raised its quarterly cash dividend to 39 cents a share from 38 cents in the year-earlier period. The new dividend will be payable March 5 to shareholders of record as of Jan. 29.

Pfizer raises quarterly cash dividend to 39 cents a share vs. 38 cents

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE:PFE) declared a 39-cent first-quarter 2021 dividend on the company's common stock, payable March 5, 2021, to holders of the Common Stock of record at the close of business on January 29, 2021. Pfizer increased the dividend over the fourth-quarter 2020 dividend by approximately 3 percent to 39 cents from 38 cents per share. The first-quarter 2021 cash dividend will be the 329th consecutive quarterly dividend paid by Pfizer. T

Pfizer Declares First-Quarter 2021 Dividend

Inovio Pharmaceuticals

Seres Therapeutics

Novavax

Twist Bioscience Corp

Investors favored coronavirus vaccine work, late-stage trial victories, and genetic sequencing.

These 5 Mid-Cap Healthcare Stocks Had the Best Gains in 2020

Here's what really matters from the FDA advisory committee's historic vote on Thursday.

FDA Committee Gives Thumbs Up for Pfizer's COVID Vaccine: 3 Most Important Things to Know

With all eyes on its COVID vaccine candidate, another drug may have more impact on the company's fate -- and its stock price.

Here's What Investors Need To Know Before Buying Pfizer Stock For Its Coronavirus Vaccine

Pfizer Inc (NYSE: PFE and BioNTech SE (NASDAQ: BNTX) have got the green light on their COVID-19 vaccine from an external panel of experts that advise the United States Food and Drug Administration. What Happened: The Vaccines and Related Biological Products Advisory Committee (VRBPAC)  voted by a large majority of 17 to 4 in favor of giving emergency use authorization (EUA) to the companies' coronavirus vaccine.

Pfizer-BioNTech COVID-19 Vaccine Gets FDA Advisors' Nod

NEW YORK and MAINZ, GERMANY, December 10, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted (17 to 4) in support of the FDA granting Emergency Use Authorization (EUA) for the companies' COVID-19 mRNA vaccine (BNT162b2). There is one member of the Committee whose vote is not included in the 17 to 4 vote decision.

Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.

Pfizer's vaccine now has the blessing of the FDA's advisory council, an important step in moving toward approval. A panel of vaccine and infectious disease experts advising the Food and Drug Administration voted to approve Pfizer's COVID-19 vaccine for anyone 16 years and above.

FDA advisory council signals support for Pfizer's COVID-19 vaccine

The final green light decision now rests in the FDA's hands.

FDA Advisory Committee Recommends Emergency Authorization for Pfizer's COVID Vaccine

The vote is the final step needed before the FDA makes it's approval decision, which could happen as soon as Friday.

FDA Advisory Committee Recommends Authorization of Pfizer's Covid Vaccine

Now it's up to the FDA to decide whether to accept that recommendation. Pfizer says the vaccine has shown 95% effectiveness in clinical trials.

FDA panel backs Pfizer's COVID-19 vaccine for emergency use in US

The Food and Drug Administration will now make the final decision on whether to authorize the experimental vaccine.

Medical experts vote in favor of FDA authorization of BioNTech/Pfizer COVID-19 vaccine candidate

An independent panel of experts has recommended Food and Drug Administration (FDA) has now voted to approve an official Emergency Use Authorization (EUA) for the Pfizer/BioNTech COVID-19 vaccine. This means that it's one step closer to beginning to be administered to people in special circumstances – including for front-line healthcare workers dealing with healthcare facilities […]

FDA panel recommends approving Pfizer's COVID-19 vaccine emergency use authorization

A committee of 22 leading scientists and doctors just voted 17 to 4, with one abstention, encouraging the US Food and Drug Administration to grant emergency use authorization for Pfizer's COVID-19 vaccine in the US. Their vote is not a final verdict, it's really just advice.

An influential expert panel just gave its blessing to Pfizer's 2-dose coronavirus shot, teeing up the FDA to imminently authorize the US' first COVID-19 vaccine

The US government advisory panel has recommended the Pfizer COVID-19 be approved for use.

Pfizer COVID-19 vaccine recommended for approval by US government advisory panel

AstraZeneca

Moderna

The time to pick your horse in the vaccine race was months ago. These stocks were much cheaper before their trials started.

The Question to Ask About COVID-19 Vaccine Stocks

Two people reported severe allergic reactions to Pfizer and BioNTech's Covid-19 vaccine when it was rolled out in the U.K.

How Safe Is Pfizer's Covid-19 Vaccine? Here's What You Should Know About Reports Of Allergic Reactions In Britain

A flurry of rumors online has prompted concern. But scientists assert the claims are baseless.

No, there isn't evidence that Pfizer's vaccine causes infertility.

The Bell's palsy related side-effects are not alarming enough to preclude FDA from granting emergency approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine.

Pfizer/BioNTech COVID-19 Vaccine Raises New Safety Concerns

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the New England Journal of Medicine has published safety and final efficacy results from the pivotal Phase 3 trial of BNT162b2, their mRNA-based COVID-19 vaccine candidate. In the trial of 43,448 participants, who were 16 years and older, 21,720 of whom received BNT162b2 and 21,728 placebo, the two-dose regimen of 30 μg BNT162b2, which was given 21 days apart, was well-tolerat

Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine

AbbVie

Bristol-Myers

Johnson & Johnson

Merck

Many prognosticators across Wall Street feel that interest rates will start to rise in 2021 Deutsche Bank is negative on duration and sees the 10-year Treasury bond yield rising to 1.5% in the second quarter of 2021 from the current yield of 0.95%.

News for Pfizer Stock (PFE)